Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin
about
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymeraseBroad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley FeverT-705 (favipiravir) inhibition of arenavirus replication in cell cultureProgress in the experimental therapy of severe arenaviral infectionsEvaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic feverEffective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic FeverFavipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic feverCombination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.Antiviral strategies for pandemic and seasonal influenzaNeurological suppression of diaphragm electromyographs in hamsters infected with West Nile virus.Pathology of experimental Machupo virus infection, Chicava strain, in cynomolgus macaques (Macaca fascicularis) by intramuscular and aerosol exposure.Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants.Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.Discovery of a novel TLR2 signaling inhibitor with anti-viral activity.T-705 (favipiravir) activity against lethal H5N1 influenza A virusesDevelopment of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog.Novel approaches in anti-arenaviral drug developmentAssessing changes in vascular permeability in a hamster model of viral hemorrhagic fever.Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease modelsMaporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir.Improving attrition rates in Ebola virus drug discovery.Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever virusesInnate immune response to arenaviral infection: a focus on the highly pathogenic New World hemorrhagic arenaviruses.Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.Highlights in antiviral drug research: antivirals at the horizon.Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions.Current drug discovery strategies against arenavirus infections.Potential and emerging treatment options for Ebola virus disease.Characterization of RNA aptamers directed against the nucleocapsid protein of Rift Valley fever virus.Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Ribavirin can be mutagenic for arenaviruses.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.Determining the Virus Life-Cycle Stage Blocked by an Antiviral.Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.
P2860
Q21089768-BAB97357-42A1-4D53-89E9-1B8924E510E5Q21092271-66DBD702-A84B-4E23-8475-A2A2322F75B3Q24633241-06DA07BA-908D-42DC-88DC-BB6B02CF8BC8Q27024953-90190D53-BB51-4D3C-843C-14B432A3D19FQ27457152-6AA4EFC3-F4F8-4F22-9B8D-BF6B45CBAAABQ28477434-DFF00127-C11F-41F5-AB46-21C31F8C6F10Q28537976-47AFA3A4-D14A-4273-84B0-223511FFB9E8Q30364319-92004D0F-316F-4881-90D8-6802C606EE45Q30408116-4D75C06B-5EBF-4E43-BE9A-16EF7F6FBE38Q30474961-3D64D139-F10C-4AF9-89F1-8F82FBCC03B6Q33416246-42AA9283-9797-41F5-9625-50C08FB1D582Q33458341-ADEB6901-9EF2-4190-ACC1-C9F33CB45DE6Q33570326-CF67EFEE-0D08-42CF-AC7C-D8DC285646D2Q33625617-DB601696-963F-4FD0-BF0B-CB0460D8D589Q33639979-2A01ED7C-C91A-4874-87A2-29420EF4E7E9Q33700461-FAD93880-98D8-491B-8C06-46034D053649Q33779739-926F7DDF-6C9D-4795-AA89-8D1402A6F1EAQ34174543-AC36B8D2-A11A-4E30-9E49-64FEED81F0C0Q34274569-C4A3C1DE-DAE5-4F7E-A277-C62FE7C91CADQ34374652-997A50A9-3D0F-4077-9802-5ADA29490898Q34432483-0605B6CA-5108-4C5E-A2A2-F6FFD4F5BDAFQ35624775-07B6092E-26A1-4122-8450-B821A2D82BE0Q35678774-21928EB7-2A50-47D5-B4C3-8375C66DF3E6Q35870592-B767EDE2-8208-40AD-858F-54F4117B8075Q35952190-F5DAA508-79D7-4F6D-9B12-00966ECB92C8Q36146469-A47FC06D-D4E7-4258-8B54-57A61C143A71Q36494323-DE367C32-39F9-49B7-86AD-4BC8D6BAC46EQ37394607-DF0CBF0D-7D6D-41FF-B9BB-D3C58A88B751Q37828538-F9984327-92F6-4F3D-9B72-05F4E4AC7E56Q37912497-9170573D-030A-4A4D-A23A-A5DA2ED3ABBAQ38007145-2E3EE6CC-1A29-4CA1-A748-7CAF227C4CBFQ38064285-448D0452-F0B7-4118-996B-504F9A3B64B4Q38067504-719B8E6F-86B0-4FD0-8345-FBE7786318AFQ38270149-F71B2F4C-C6EF-4699-809A-C37A7E16DB18Q38328619-A6954F1E-EBBA-4200-831D-CA4F8DC31EBAQ38833628-CD322E95-3AE3-451A-8996-C3C9A6C00773Q39544616-7BFBEDE7-C4A8-4B35-BCE2-B4187F2EB460Q40044875-00A461B6-6D7D-4E2A-86B6-F881EE37A6C7Q41922323-41092181-6A50-4015-B964-8618E54E395AQ45324172-CD98E9E4-1DD6-4DE4-8022-ECC30E2A38DA
P2860
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Treatment of late stage diseas ...... ts an alternative to ribavirin
@ast
Treatment of late stage diseas ...... ts an alternative to ribavirin
@en
Treatment of late stage diseas ...... ts an alternative to ribavirin
@nl
type
label
Treatment of late stage diseas ...... ts an alternative to ribavirin
@ast
Treatment of late stage diseas ...... ts an alternative to ribavirin
@en
Treatment of late stage diseas ...... ts an alternative to ribavirin
@nl
prefLabel
Treatment of late stage diseas ...... ts an alternative to ribavirin
@ast
Treatment of late stage diseas ...... ts an alternative to ribavirin
@en
Treatment of late stage diseas ...... ts an alternative to ribavirin
@nl
P2093
P2860
P1433
P1476
Treatment of late stage diseas ...... ts an alternative to ribavirin
@en
P2093
Brian B Gowen
Jeffery O Hall
John R Stevens
Kevin W Bailey
Kie-Hoon Jung
Min-Hui Wong
Yousuke Furuta
P2860
P356
10.1371/JOURNAL.PONE.0003725
P407
P577
2008-01-01T00:00:00Z